, Clause 38, Clause 43(3), and Clause 44 of the Notification of the Capital Market Supervisory Board No. Tor Thor. 35/2556 Re: Standard Conduct of Business, Management Arrangement, Operating Systems and
The financial statements for the first quarter ended March 31, 2020 were prepared in accordance with the Thai Financial Reporting Standard No.9 Financial Instruments (TFRS 9) and Thai Financial
Including other income and share of profit from investments in associates and JVs /2 Gross profit including share of profit from investments in associates and JVs /3 Normalized Total Revenue = Total Revenue
standard, resulting to the increase of interest expense from the same quarter of the previous year. In this quarter, the Company had no amount of share of profit from investments in associates but recorded
total registered capital) (“Prime-A”) amounted to 50,000 shares at the par value of Baht 100 per share, which is equivalent to 50 percent of the total shares in Prime-A; and assigned the claim on the
) (282) -31% Net profit attributable to owners of the parent 620 370 68% (1,546) 140% 1,732 2,463 -30% Basic earnings per share (Baht) 0.38 0.27 (1.12) 1.18 1.79 Note: 1/ EBITDA from Refinery Business of
Distribution of Newly Issued Shares and Share Warrants by Issuer
11,638.0 (198.0) (1.7%) Normalized Net Profit/3 2,864.7 2,917.9 53.2 1.9% /1 Including other income and share of profit from investments in associates and JVs /2 Gross profit including share of profit from
- Translation- June 11, 2019 Subject: Notification the Acquisition of share of BS Myco Biotech Company Limited. (Additional Information Memorandum Concerning the Acquisition of Assets) To: Director and Manager
องทุนรวมประเภทเฮ็ดจฟนด (Hedge fund) กองทุน Morgan Stanley Investment Funds US Advantage Fund (กองทุนหลัก) แบงหนวย ลงทุนท่ีเสนอขายออกเปน Share Class ซึ่งจะแตกตางกันท่ีรายละเอียดตางๆ เชน มูลค